Form D · Other Health Care
Alcyone Therapeutics, Inc.
Lowell, MA · CIK 0001544927
Offering snapshot reported Jan 8, 2025 · SEC filing
- Reported sold
- $19M Offering amount: $31.6M
- Investors reported
- 25 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 7, 2023 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$17,257,814 → $19,032,812
- Reported investors22 → 25
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 8, 2025 | Amendment | $19,032,812 | $1,774,998vs Nov 22, 2023 | 25 | SEC filing |
| Nov 22, 2023 | Initial | $17,257,814 | No comparison | 22 | SEC filing |
| Jun 17, 2021 | Initial | $37,103,349 | No comparison | Not reported | SEC filing |
| Sep 2, 2020 | Initial | $17,550,174 | No comparison | 28 | SEC filing |
| Jul 3, 2019 | Initial | $2,208,330 | No comparison | 17 | SEC filing |
| Apr 11, 2019 | Initial | $1,650,000 | No comparison | 17 | SEC filing |
| Jan 17, 2018 | Initial | $5,140,609 | No comparison | 22 | SEC filing |
| Dec 24, 2015 | Initial | $3,640,319 | No comparison | 20 | SEC filing |
| Jan 13, 2014 | Initial | $4,000,000 | No comparison | 19 | SEC filing |
| May 20, 2013 | Initial | $1,000,004 | No comparison | 18 | SEC filing |
| Mar 27, 2012 | Initial | $1,835,007 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $253K (estimated)
- Form D file number
- 021-497946
Includes conversion of outstanding Convertible Notes into shares of Preferred Stock.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Brookline Capital Markets | 44656 | Arcadia Securities, LLC · CRD 44656 |
Source: Form D, filed Jan 8, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Pj Anand | Director, Executive |
| David Donabedian | Director |
| Cameron Durrant | Director |
| Edgar D. Jannotta | Director |
| Edgard Jannotta, Jr. | Director |
| Edgar Jannotta, Jr. | Director |
| Stephen Oesterle | Director |
| Piratip Pratumsuwan | Director |
| Norbert Riedel | Director |
| Richard Upton | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
116 John Street Suite 300
Lowell, MA, 01852
Lowell, MA, 01852